{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T22:10:05Z","timestamp":1733609405401,"version":"3.30.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ijcha.2024.101448","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T16:22:41Z","timestamp":1719073361000},"page":"101448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Eligibility of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction: Insights from the Colombian heart failure registry (RECOLFACA)"],"prefix":"10.1016","volume":"53","author":[{"given":"Juan Esteban","family":"G\u00f3mez-Mesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Saldarriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Arnulfo","family":"Rivera-Toquica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silfredo","family":"Arrieta-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Mu\u00f1oz-Vel\u00e1squez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Jos\u00e9","family":"Echeverry-Navarrete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli\u00e1n Rodrigo","family":"Lugo-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Alberto","family":"Cer\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar Sveins","family":"Rinc\u00f3n-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Eduardo","family":"Silva-Diazgranados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo Ernesto","family":"Osorio-Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Posada-Bastidas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Camilo","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro David","family":"Ochoa-Mor\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Eduardo","family":"Echeverr\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2024.101448_b0005","doi-asserted-by":"crossref","first-page":"s24","DOI":"10.7861\/clinmedicine.18-2-s24","article-title":"Heart failure with preserved ejection fraction","volume":"18","author":"Harper","year":"2018","journal-title":"Clin. Med."},{"key":"10.1016\/j.ijcha.2024.101448_b0010","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure: A Report From the OPTIMIZE-HF Registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101448_b0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/eurjhf\/hft062","article-title":"How do patients with heart failure with preserved ejection fraction die?","volume":"15","author":"Chan","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2024.101448_b0020","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1161\/CIRCULATIONAHA.108.815944","article-title":"Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute","volume":"119","author":"Lee","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2024.101448_b0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2024.101448_b0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","article-title":"Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial","volume":"114","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ijcha.2024.101448_b0035","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2024.101448_b0040","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.ijcha.2024.101448_b0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2021.08.035","article-title":"Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction","volume":"341","author":"Monzo","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101448_b0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ehf2.12528","article-title":"Eligibility of sodium\u2013glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure","volume":"7","author":"Sharma","year":"2020","journal-title":"ESC Heart Fail."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101448_b0055","first-page":"217","article-title":"RECOLFACA Research Group. Colombian heart failure registry (RECOLFACA): methodology and preliminary data","volume":"28","author":"Gomez-Mesa","year":"2021","journal-title":"Rev Colomb Cardiol."},{"key":"10.1016\/j.ijcha.2024.101448_b0060","unstructured":"StataCorp. Stata Statistical Software. College Station, TX: StataCorp LLC. 2017."},{"issue":"9","key":"10.1016\/j.ijcha.2024.101448_b0065","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s13300-020-00889-9","article-title":"Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther."},{"issue":"10","key":"10.1016\/j.ijcha.2024.101448_b0070","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.ijcha.2024.101448_b0075","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2024.101448_b0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2024.101448_b0085","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2024.101448_b0090","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2024.101448_b0095","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jchf.2020.04.008","article-title":"Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril\/Valsartan: The DAPA-HF Trial","volume":"8","author":"Solomon","year":"2020","journal-title":"JACC Heart Fail."},{"issue":"5","key":"10.1016\/j.ijcha.2024.101448_b0100","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.hlc.2020.10.012","article-title":"The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis","volume":"30","author":"Nie","year":"2021","journal-title":"Heart Lung Circ."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101448_b0105","first-page":"1","article-title":"Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry","volume":"6","author":"Vaduganathan","year":"2020","journal-title":"JAMA Cardiol."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724001143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724001143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T21:49:32Z","timestamp":1733608172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906724001143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":21,"alternative-id":["S2352906724001143"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101448","relation":{},"ISSN":["2352-9067"],"issn-type":[{"type":"print","value":"2352-9067"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eligibility of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction: Insights from the Colombian heart failure registry (RECOLFACA)","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101448","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101448"}}